Mdma molecule:

Image from PubChem

Mdma Clinical Trials

Open-labeled Dose-extending Placebos as an Adjunct to Methadone Treatment: A Pilot Study

To see complete record on, please visit this link

Id: NCT02941809

Organisation Name: University of Maryland, Baltimore

Overal Status: Completed

Start Date: December 5, 2017

Last Update: August 11, 2020

Lead Sponsor: University of Maryland, Baltimore

Brief Summary: More than 2 million individuals in the United States have an Opioid Use Disorder (OUD). Methadone maintenance treatment is the gold standard of medication-assisted treatment for OUD, but high-dose methadone is associated with cardiotoxicity and respiratory complications, among other side effects. These adverse effects make enhancing the effectiveness of lower doses of methadone an attractive therapeutic goal. Long recognized for its capacity to enhance treatment outcomes for a wide range of neuropsychiatric disorders including pain, the placebo effect offers an as-yet untested avenue to such an enhancement. This approach is particularly compelling given that individuals with substance use disorder tend to have higher salience attribution, and may thereby be more sensitive to placebo effects. Our study combines two promising clinical methodologies-open-label placebo and conditioning-to investigate whether placebo effects can increase the effective potency of methadone in treatment-seeking OUD patients.

  • Opioid-use Disorder
  • Opioid-Related Disorders

Total execution time in seconds: 0.30039000511169